水飞蓟宾治疗药物性肝损伤的研究进展

邵爽; 刘春燕; 高沿航

doi:10.3969/j.issn.1001-5256.2017.06.035

水飞蓟宾治疗药物性肝损伤的研究进展

DOI: 10.3969/j.issn.1001-5256.2017.06.035

吉林大学第一医院肝病科

详细信息

中图分类号: R575
计量
- 文章访问数: 2086
- HTML全文浏览量: 35
- PDF下载量: 509
- 被引次数: 0
出版历程
- 收稿日期: 2017-01-27
- 出版日期: 2017-06-20

Research advances in silybin in treatment of drug-induced liver injury

Department of Hepatology, The First Hospital of Jilin University

摘要

摘要: 药物性肝损伤是临床上常见的肝损伤类型,抗精神病类药物、抗结核药物、对乙酰氨基酚、他汀类药物等均可能引起药物性肝损伤。水飞蓟宾作为水飞蓟素提取物中最具生物活性的物质,具有抗氧化、抗炎、抗纤维化等作用,总结了水飞蓟宾在防治药物性肝损伤方面的研究进展。
- 药物性肝损伤 /
- 水飞蓟素 /
- 综述
Abstract: Drug-induced liver injury is commonly seen in clinical practice and is usually caused by antipsychotic drugs, antitubercular agents, paracetamol, and statins. Silybin, a substance with biological activity in silymarin extract, has antioxidant, anti-inflammatory, and anti-fibrosis effects. This article summarizes the research advances in silybin in the prevention and treatment of drug-induced liver injury.
- drug induced liver injury /
- silymarin /
- review

HTML全文

参考文献(38)

[1]PANDIT A, SACHDEVA T, BAFNA P.Drug induced hepatoxicity:a review[J].J Appl Pharm Sci, 2012, 2 (5) :233-243.

[2]LOGUERCIO C, FESTI D.Silybin and the liver:From basic research to clinical practice[J].World J Gastroenterol, 2011, 17 (18) :2288-2301.

[3]TROUILLAS P, MARSAL P, SVOBODOVA, et al.Mechanism of the antioxidant action of silybin and 2, 3-dehydrosilybin flavonolignans:a joint experimental and theoretical study[J].J Phys Chem A, 2008, 112 (5) :1054-1063.

[4]ABENAVOLI L, CAPASSO R, MILIC N.Milk thistle in liver diseases:past, present, future[J].Phytother Res, 2010, 24 (10) :1423-1432.

[5] LOGUERCIO C, FESTI D.Silybin and the liver:from basic research to clinical practice[J].World J Gastroenterol, 2011, 17 (18) :2288-2301.

[6]HAN X, WANG Z, WANG M.Liver-targeting self-assembled hyaluronic acid-glycyrrhetinic acid micelles enhance hepato-protective effect of silybin after oral administration[J].Drug Deliv, 2016, 23 (5) :1818-1829.

[7]DEEP G, AGARWAL R.Antimetastatic efficacy of silibinin:molecular mechanisms and therapeutic potential against cancer[J]Cancer Metast Rev, 2010, 29 (3) :447-463.

[8]LIGERET H, BRAULT A, VALLERAND D, et al.Antioxidant and mitochondrial protective effects of silibinin in cold preservation-warm reperfusion liver injury[J].J Ethnopharmacol, 2008, 115 (3) :507-514.

[9]LUANGCHOSIRI C, THAKKINSTAIN A, CHITPHUK S, et al.A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury[J].BMC, 2015, 15:334.

[10]GHARAGOZLOO M, KHOSHDEL Z, AMIRGHOFRAN Z.The effect of an iron (III) chelator, silybin, on the proliferation and cell cycle of Jurkat cells:a comparison with desferrioxamine[J].Eur J Pharmacol, 2008, 589 (1-3) :1-7.

[11]GHARAGOZLOO M, VELARDI E, BRUSCOLI S, et al.Silymarin suppress CD4+T cell activation and proliferation:effects on NFkappa B activity and IL-2 production[J].Pharmacol Res, 2010, 61 (5) :405-409.

[12]TRAPPOLIERE M, CALIGIURI A, SCHMID M, et al.Silybin, a component of sylimarin, exerts antiinflammatory and anti-fibrogenic effects on human hepatic stellate cells[J].J Hepatol, 2009, 50 (6) :1102-1111.

[13]DETAILLE D, SANCHEZ C, SANZ N, et al.Interrelation between the inhibition of glycolytic flux by silibinin and the lowering of mitochondrial ROS production in perifused rat hepatocytes[J].Life Sci, 2008, 82 (21-22) :1070-1076.

[14]NOMURA M, TAKAHASHI T, NAGATA N, et al.Inhibitory mechanisms of flavonoids on insulin-stimulated glucose uptake in MC3T3-G2/PA6 adipose cells[J].Biol Pharm Bull, 2008, 31 (7) :1403-1409.

[15] LOGUERCIO C, FESTI D.Silybin and the liver:from basic research to clinical practice[J].World J Gastroenterol, 2011, 17 (18) :2288-2301.

[16]PRADHAN SC, GIRISH C.Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine[J]J Med Res, 2006, 124 (5) :491-504.

[17]FEHRENBACH T, CUI Y, FAULSTICH H, et al.Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins[J].Naunyn Schmiedebergs Arch Pharmacol, 2003, 368 (5) :415-420.

[18]EBESTIAN J, EBESTIANOVB, MOULISOVV, et al.The role of cyclosporines and silymarines structures for their interactions with lipids of hepatocyte plasma membrane[J].Mater Struct, 2004, 11 (1) :15-17.

[19]TEDESCO D, DOMENEGHINI C, SCIANNIMANICO D, et al.Silymarin, a possible hepatoprotector in dairy cows:biochemical and histological observations[J].J Vet Med A Physiol Pathol Clin Med, 2004, 51 (2) :85-89.

[20]ZHANG H.Clinical effect of silibinin in treatment of liver injury induced by antipsychotic drugs[J].Xinjiang Med J, 2014, 44 (10) :27-28. (in Chinese) 张红.水飞蓟宾治疗抗精神病药物引起的肝功能损害的疗效观察[J].新疆医学, 2014, 44 (10) :27-28.

[21]KIM NC, GRAF TN, SPARACINO CM, et al.Complete isolation and characterization of silybins and isosilybins from milk thistle (silybum marianum) [J].Org Biomol Chem, 2003, 1:1684-1689.

[22] AWODELE O, AGBAJE EO, ADESINA EA, et al.Hepatoprotective roleof neutrosecR on hepatic damage induced by combination of zidovudine andcombined anti-tuberculous agents in rat[J].Tokai J Exp Clin Med, 2011, 36 (2) :31-36.

[23]SHARIFZADEH M, RASOULINEJAD M, VALIPOUR F, et al.Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberculosis treatment[J].Pharmacol Res, 2005, 51 (4) :353-358.

[24]AWODELE O, AGBAJE EO, ADESINA EA, et al.Hepatoprotective role of neutrosecR on hepatic damage induced by combination of zidovudine and combined anti-tuberculous agents in rats[J].Tokai J Exp Clin Med, 2011, 36 (2) :31-36.

[25]SHI QH, ZHOU BG, GUO P, et al.Preventive effect of silibinin against liver injury induced by anti-tuberculosis drugs:a meta-analysis[J].Shandong Med J, 2016, 56 (8) :44-46. (in Chinese) 石清红, 周本刚, 郭鹏, 等.水飞蓟宾预防抗结核药所致肝损伤效果的Meta分析[J].山东医药, 2016, 56 (8) :44-46.

[26] DUAN HQ.Preventive effect of silibinin capsules against drug-induced liver injury in hepatitis B virus carriers[J].J Chin Tradit Chin Med Inf, 2009, 1 (4) :88. (in Chinese) 段宏秋.水飞蓟宾胶囊预防乙型肝炎病毒携带者药物性肝损伤的临床疗效[J].中国中医药咨讯, 2009, 1 (4) :88.

[27]GU J, TANG SJ, TAN SY, et al.An open-label, randonmized and multi-center clinical trial to exaluate the efficacay of Silibinin in preventing drug-induced liver injury[J].J Clin Exp Med, 2015, 8 (3) :4320-4327.

[28]LEE WS, Mc KIERMAN P, KELLY D.Etiology, outcome and prognostic indicators of childhood fulminant hepatic failure in the United Kingdom[J].J Pediat Gastroenterol Nutr, 2005, 40 (5) :575-581.

[29]TOES MJ, JONES AL, PRESCOTT L.Drug interactions with paracetamol[J].Am J Ther, 2005, 12 (1) :56-66.

[30]BARLETT D.Acetaminophen toxicity[J].J Emerg Nurs, 2004, 30 (3) :281-283.

[31]DARGAN PI, JONES AL.Management of paracetamol poisoning[J].Trends Pharmacol Sci, 2003, 24 (4) :154-157.

[32]ZIRA A, MIKROS E, GIANNIOTI K, et al.Acute liver acetaminophen toxicity in rabbits and the use of antidotes:a metabonomic approach in serum[J].J Appl Toxicol, 2009, 29 (5) :395-402.

[33]LEWERENZ V, HANELT S, NASTEVSKA C, et al.Antioxidants protect primary rat hepatocyte cultures against acetaminophen-induced DNA strand breaks but not against acetaminophen-induced cytotoxicity[J].Toxicology, 2003, 191 (2-3) :179-187.

[34]OKADA Y, YAMAGUCHI K, NAKAJIMA T, et al.Rosuvastatin ameliorates high-fat and high-cholesterol diet-induced nonalcoholic steatohepatitis in rats[J].Liver Int, 2013, 33 (2) :301-311.

[35]RUSSO MW, HOOFNAGLE JH, GU J, et al.Spectrum of statin hepatotoxicity:experience of the drug-induced liver injury network[J].Hepatology, 2014, 60 (2) :679-686.

[36]BJRNSSON E, JACOBSEN EI, KALAITZAKIS E.Hepatotoxicity associated with statins:reports of idiosyncratic liver injury postmarketing[J].J Hepatol, 2012, 56 (2) :374-380.

[37]PERDICES EV, MEDINA-CLIZ I, HERNANDO S, et al.Hepatotoxicity associated with statin use:analysis of the cases included in the spanish hepatotoxicity registry[J].Rev Esp Enferm Dig, 2014, 106 (4) :246-254.

[38]WANG LY, HUANG YS, PERNG CL.Statin-induced liver injury in an area endemic for hepatitis B virus infection:risk factors and outcome analysis[J].Br J Clin Pharmacol, 2016, 82 (3) :823-830.

施引文献

资源附件(0)

访问统计